Absence of Evidence: SkQ1 (Visomitin) for AMD
"Absence of evidence is not evidence of absence." — Carl Sagan
The Treatment Gap in AMD
Current standard of care for Age-Related Macular Degeneration (AMD) focuses exclusively on symptom management rather than addressing the underlying cause. This creates a significant gap in patient outcomes.
| Feature | Standard of Care | The Gap | SkQ1 Potential |
|---|---|---|---|
| Targets Root Cause | No | Mitochondrial dysfunction ignored | Yes |
| Treats Dry AMD | No effective treatment | 85-90% of patients left untreated | Preclinical evidence |
| Restores Function | Slows decline only | No reversal mechanism | Normalizes VEGF/PEDF |
| Prevents Progression | Limited | 63.3% still lose vision | Prevents pathology |
The Clinical Reality: When Standard of Care Fails
Current Treatment Outcomes
63.3% of eyes treated with anti-VEGF injections still lose ≥15 letters of vision over 2 years.
11.7 hours per year average burden on patients and caregivers for clinic visits and injections.
Despite being the "gold standard," anti-VEGF therapy:
- Does not address the root cause (mitochondrial oxidative stress)
- Requires invasive, repeated intravitreal injections
- Offers no solution for Dry AMD (85-90% of cases)
- Suppresses VEGF rather than restoring natural balance
Mitochondrial Dysfunction: The Root Cause
The pathogenesis of AMD begins with mitochondrial oxidative stress in the Retinal Pigment Epithelium (RPE). This is not speculation—it is established science.
The Cascade:
- Mitochondrial ROS accumulation → Damages RPE cells
- RPE dysfunction → Disrupts VEGF/PEDF balance
- VEGF overexpression → Neovascularization (Wet AMD)
- Chronic inflammation → Drusen formation (Dry AMD)
Key Insight: Current treatments target Step 3 (VEGF). SkQ1 targets Step 1 (Mitochondrial ROS).
SkQ1: A Mitochondria-Targeted Antioxidant
SkQ1 (Visomitin) is a rechargeable antioxidant that selectively accumulates in mitochondria at concentrations 1000x higher than in the cytoplasm.
Mechanism of Action:
- Penetrates mitochondrial membrane via lipophilic cation structure
- Neutralizes ROS at the source (Complex I/III of electron transport chain)
- Restores VEGF/PEDF balance by reducing oxidative stress signals
- Prevents RPE apoptosis and choroidal degradation
Preclinical Evidence
In OXYS rats (a validated AMD model), SkQ1 eye drops:
- Prevented pathological changes in RPE and choroid
- Normalized VEGF and PEDF expression (not ablated)
- Restored αB-crystallin levels (cellular protection)
- Reversed early-stage retinopathy
Why No Phase 3 Trials? The Economic Reality
The absence of large-scale clinical trials for SkQ1 is not a reflection of its scientific merit. It is a consequence of economic incentives.
| Factor | Reality |
|---|---|
| Phase 3 Trial Cost | $50-100 million USD |
| Patent Status | Expired (no exclusivity) |
| Market Size | Large, but no monopoly pricing |
| ROI for Pharma | Negative (generics can copy immediately) |
The Epistemological Trap
The Fallacy: "There are no Phase 3 trials, therefore SkQ1 does not work."
The Reality: "There are no Phase 3 trials because the patent expired, removing the financial incentive to fund them."
What We DO Have:
- Valid Mechanism: Targets mitochondrial ROS directly
- Animal Models: Prevents AMD-like pathology in OXYS rats
- Safety Data: Phase 2 trials in Russia (dry eye syndrome)
- Biological Plausibility: Peer-reviewed in Antioxidants, PLoS One, Biochemistry
SkQ1 Occupies the "Absence of Evidence" Zone
This matrix illustrates why SkQ1 lacks clinical trials despite strong biological rationale:
Key Observation: SkQ1 sits in the top-left quadrant—high biological potential, but low commercial incentive. This is where promising therapies go to die in our current pharmaceutical system.
When Standard of Care Fails: A Patient Case Study
The Prognosis
After exhausting standard treatments, my mother's ophthalmologists confirmed there was nothing more they could do. The prognosis was total blindness.
The SkQ1 Result (3.5 Weeks)
After starting Visomitin drops (SkQ1), her condition began reversing. "She is seeing things she could not see 4 weeks ago."
Disclaimer: I am a molecular biologist with a background in cancer therapeutics (therapeutic apheresis), not an ophthalmologist. I am not providing medical advice. I am reporting a functional outcome in a case where standard care had failed.
Sourcing SkQ1 (Visomitin)
Status: Not in US Pharmacies
Visomitin is a Russian product. Financial sanctions and tariffs make it difficult to obtain through standard channels.
Where to Buy
I have successfully ordered twice from RuPharma (International Pharmacy).
Note: Payment often requires Bitcoin/Crypto due to credit card restrictions on Russian vendors. I received a 10% discount using Bitcoin.
Questions? Email me at: chordlow@gmail.com
Key Scientific References
The Path Forward
For Patients
Advocate for options based on biological logic when standard protocols fail. The absence of a Phase 3 trial does not mean the absence of hope.
For Medicine
Recognize that "No Evidence" often simply means "No Commercial Incentive." We must find ways to validate promising therapies that fall outside the patent system.
For Science
Shift focus from suppressing symptoms (VEGF ablation) to restoring mitochondrial health. This is the future of regenerative ophthalmology.
